News

In part 2 of a 2-part article, Arun C. Gulani, MD, walks through the 4 patient types of the Gulani classification of refractive lens exchange, from primary vision enhancement to staged vision engineering, and explains why outcomes depend on treating the eye as a complete optical system rather than on the implant alone.

The annual Best Hospitals report from US News & World Report compares more than 4500 hospitals across 14 specialties and 22 procedures and conditions.

Andrew G. Lee, MD, and Drew Carey, MD, discuss a study exploring whether these two conditions are really one disease—and what that means for long-term treatment.

The first half of 2026 turned on inherited pediatric eye disease, with 2 gene therapy programs advancing toward registration and a high-profile complete response letter in a childhood-onset optic neuropathy.

The FDA has cleared an IND for RAG-1C, a first-in-class saRNA therapy targeting proliferative vitreoretinopathy.

Home OCT now gives us the next dimension: time.

Retina specialists Baruch D. Kuppermann, MD, PhD, and Firas M. Rahhal, MD, discuss the significance of bevacizumab-vikg's approval for wet AMD and its impact on physicians and patients.

Seven-year Vestrum data: anti-VEGF gaps hit 40% of wet AMD patients by year one, worsening vision.

An investigational drug has shown positive activity against metastatic uveal melanoma in a phase 1 study.

Findings highlight the need for routine bilateral endothelial assessment in herpetic eye disease

Choosing the right IOL for patients seeking spectacle independence is increasingly complex as novel optical designs enter the field. This comparative case report explores how a proven diffractive trifocal IOL (AT LISA tri 839MP) performs against a novel spiral optic IOL and what the real-world trade-offs mean for patient selection.

Shortcomings of early 27-G vitrectomy systems drove the development of new technologies designed to match or surpass the performance of larger-gauge systems. The DORC TDC VELOCE represents the latest advancement - a next-generation high-speed cutter that reaches its full potential when combined with the DORC EVA NEXUS surgical system.

Jordana Fein, MD, MS, presented 64-week QUASAR data showing aflibercept 8 mg sustained visual acuity gains with up to 3 fewer injections than aflibercept 2 mg in macular edema following RVO.

When patients fall outside pivotal clinical trial criteria, retina specialists factor in real-world judgment to guide treatment.

A single vorolanib intravitreal insert extended time to supplemental anti-VEGF injection vs aflibercept in previously treated DME at 24 weeks in phase 2 VERONA; pivotal phase 3 trials COMO and CAPRI are now underway.

For Caroline R. Baumal, MD, a path from academic retina through industry leadership has brought her full circle—back to the clinic with a broader view of the field.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.

The phase 2 EVIAN study (Early Vitrectomy and Intravitreal Antibiotics for Post-Operative Exogenous Endophthalmitis) (NCT 04522661) showed that performing early vitrectomy for acute endophthalmitis can offer better and faster visual outcomes than the current treament of prescribing antibiotics first.

Three cases illustrate treatment switches and extension intervals across retinal vein occlusion, age-related macular degeneration, and diabetic retinopathy.

Arun C. Gulani, MD, introduces the Gulani classification of refractive lens exchange, a 4-type framework for individualizing premium IOL selection and surgical strategy around each eye's visual potential rather than its diagnosis.

Hasenin Al-khersan, MD, of the Retina Group of Florida, shares real-world RCA registry findings showing that pegcetacoplan significantly reduced both photoreceptor and RPE loss in eyes with GA.

Susvimo works in conjunction with the company’s port delivery platform, Contivue, which was specifically engineered for use with Susvimo.

Charles Wykoff, MD, PhD, of Retina Consultants of Texas, discusses 1 year of real-world revakinagene taroretcel experience, covering patient selection, surgical technique, early safety outcomes, and the platform’s potential beyond MacTel.

Physician AI use has more than doubled since 2023—but the next leap in ophthalmology won't come from smarter diagnostic algorithms alone.

Glaukos finishes US pivotal enrollment for PRESERFLO MicroShunt, targeting advanced glaucoma after failed surgeries, with 12‑month IOP reduction data guiding FDA plans.

A study of YB-101, a potential treatment for both Graves' disease and thyroid eye disease, has begun dosing the first patients. The molecule receive Fast Track Designation from the FDA.

Outlining the benefits of modulating the gut microbiome in diabetes.